Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike

Rhea-AI Filing Summary

Biomea Fusion, Inc. reported that Interim CEO and director Michael J.M. Hitchcock received a grant of stock options covering 667,477 shares of Common Stock on April 1, 2026. The options have an exercise price of $1.49 per share and expire on March 31, 2036.

According to the terms, the option will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, as long as Hitchcock continues to serve the company through each vesting date. Following this grant, he holds 667,477 derivative securities directly.

Insights

Equity compensation analyst

Interim CEO receives multi-year stock option grant as routine equity compensation.

The filing shows Michael J.M. Hitchcock, Interim CEO and director of Biomea Fusion, Inc., receiving a stock option grant for 667,477 shares of Common Stock at an exercise price of $1.49 per share. This is classified as a grant or award, not an open-market purchase.

The options vest in 16 substantially equal quarterly installments after April 1, 2026 and become fully vested on April 1, 2030, contingent on continued service. This creates a long-term incentive structure aligned with his tenure rather than a short-term trading signal.

The derivative position expires on March 31, 2036, giving a long exercise window once vested. With 667,477 derivative securities reported as held directly after this transaction and no concurrent sales or exercises disclosed, the event appears to be standard executive equity compensation with neutral impact.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hitchcock Michael J.M.

Role Interim CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	667,477	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 667,477 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 667,477 options Exercise price: $1.49 per share Shares underlying options: 667,477 shares +3 more

6 metrics

Option grant size 667,477 options Grant to Interim CEO on April 1, 2026

Exercise price $1.49 per share Stock option exercise price

Shares underlying options 667,477 shares Common Stock underlying the option

Total derivative securities after grant 667,477 Directly held following transaction

Vesting schedule 16 quarterly installments After April 1, 2026 until fully vested April 1, 2030

Option expiration date March 31, 2036 Final exercise date for the grant

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, derivative securities, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.4900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The option shall vest and become exercisable in 16 substantially equal quarterly installments"

derivative securities financial

"total_shares_following_transaction shown for derivative type transaction"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hitchcock Michael J.M.

(Last) (First) (Middle)

C/O BIOMEA FUSION, INC.

1599 INDUSTRIAL ROAD

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biomea Fusion, Inc. [ BMEA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.49	04/01/2026		A		667,477		(1)	03/31/2036	Common Stock	667,477	$0	667,477	D

Explanation of Responses:

1. The option shall vest and become exercisable in 16 substantially equal quarterly installments after April 1, 2026, such that the award will be fully vested and exercisable on April 1, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Rainer Erdtmann as Attorney-in-Fact for Michael J.M. Hitchcock	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Biomea Fusion (BMEA) report in this Form 4 for its Interim CEO?

Biomea Fusion reported that Interim CEO Michael J.M. Hitchcock received a stock option grant for 667,477 shares of Common Stock. The award represents equity-based compensation rather than an open-market trade, aligning his potential future gains with the company’s share performance over time.

How many stock options did Biomea Fusion’s Interim CEO receive and at what exercise price?

Michael J.M. Hitchcock received stock options covering 667,477 shares of Biomea Fusion Common Stock, with an exercise price of $1.49 per share. This price is the cost he must pay to acquire each share once the options vest and he chooses to exercise them.

What is the vesting schedule for Michael Hitchcock’s Biomea Fusion stock options?

The stock options vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested on April 1, 2030. Vesting is conditioned on Hitchcock’s continued service to Biomea Fusion through each vesting date, tying the award to long-term employment.

When do Biomea Fusion’s newly granted options to its Interim CEO expire?

The options granted to Interim CEO Michael J.M. Hitchcock expire on March 31, 2036. After that date, any unexercised portion of the 667,477-share option grant will lapse, meaning he would no longer be able to purchase shares at the $1.49 exercise price.

Does this Biomea Fusion Form 4 show any stock sales or open-market purchases?

No sales or open-market purchases are shown; the filing reports a grant of derivative securities. It classifies the transaction as a grant or award acquisition of stock options, which is typical executive compensation rather than an indication of buying or selling shares in the open market.

How many derivative securities does Biomea Fusion’s Interim CEO hold after this transaction?

After the transaction, Interim CEO Michael J.M. Hitchcock is reported as holding 667,477 derivative securities directly. These represent stock options tied to Biomea Fusion Common Stock, subject to the specified vesting schedule and the exercise price of $1.49 per share.